Celadon Pharmaceuticals is at the forefront of developing cannabis-based medicines, focusing on improving the quality of life for patients suffering from chronic pain. The company operates a licensed 100,000 sq ft facility in the UK, where it cultivates high-THC cannabis and extracts active pharmaceutical ingredients (APIs) under EU-GMP standards. This facility enables Celadon to produce high-quality cannabinoid products for pharmaceutical use. The company is also engaged in clinical trials, notably the MHRA conditionally approved CANPAIN trial, which aims to generate robust data on the efficacy and safety of cannabis-based medicines for chronic pain management. This trial is particularly significant given the growing concerns over opioid treatments and their limited effectiveness for long-term pain relief.

In addition to its cultivation and clinical trial efforts, Celadon is committed to research and development, focusing on novel intellectual property generation and expanding its pipeline of prescription medicines. The company has formed strategic partnerships, such as with Kingdom Therapeutics, to develop licensed cannabinoid treatments for conditions like Autism Spectrum Disorder. Celadon’s integrated approach, combining cultivation, extraction, and clinical research, positions it uniquely within the pharmaceutical landscape, allowing it to address significant unmet medical needs while navigating the regulatory complexities of the cannabis industry.

United Kingdom

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of cannabis-based products, initially for the chronic pain market.

Celadon Pharmaceuticals

Company Details